How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

What’s on CS111: The final covers programming basics, data structures, algorithms, recursion, and problem-solving, often through multiple-choice and coding questions. How to prepare: Review lectures ...

Jeff Carlson writes about mobile technology for CNET. He is also the author of dozens of how-to books covering a wide spectrum ranging from Apple devices and cameras to photo editing software and ...

Finite-time control refers to the design and analysis of feedback mechanisms that drive a dynamical system’s state to a desired condition within a predetermined, finite interval. This contrasts with ...

Law firm Wiley Rein hit with class action over data breach tied to Chinese hackers Prominent U.S. law firm Wiley Rein has been sued in a proposed class action alleging the firm failed to protect ...

A good sum of two good parts. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market cycle on a ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.